Alcon to buy rights to eyecare products amid Novartis takeover turmoil
19 January 2010
Simon Varcoe
Alcon is to buy the US rights to two marketed topical eyecare products as well as the ex-Latin America rights to a product in development from the private US firm Sirion Therapeutics.
The Swiss company, itself an acquisition target by Novartis, will purchase the rights to Durezol (difluprednate...
Please Login to read the full article.
19 January 2010
Simon Varcoe
The Swiss company, itself an acquisition target by Novartis, will purchase the rights to Durezol (difluprednate...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Altacor to evaluate lead compound from Proximagen's 5HT2c programme for glaucoma
- €70 million for French VCs from Santen’s acquisition of ophthalmic firm Novagali
- InSite to raise $22M to advance PhIII pipeline including combo product for lid margin disease
- RegeneRx provides more clarity, insight into move from heart to eye focus
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
